Takeda Pharmaceuticals: Global Homepage

Takeda leads with a generational promise

to boldly reinvent for a healthier world

Unlocking a new era of impact with first-in-class treatments.

FDA approves new treatment for polycythemia vera (PV)

A new first-in-class treatment for erythrocytosis in adults with polycythemia vera (PV) marks an important milestone for the PV community and reflects significant progress for people living with this chronic blood cancer.

Learn more

MHLW approves Takeda's treatment for adults with narcolepsy type 1 (NT1)

A new chapter for narcolepsy type 1 (NT1) care and orexin science

Discovery of this new class of medicine now approved in Japan was spearheaded by Takeda in the company’s labs in Shonan.

Learn more

FDA approves Takeda’s narcolepsy type 1 medicine

A new chapter for narcolepsy type 1 (NT1) care and orexin science

We expect to make this first-in-class medicine available to the NT1 community by November 2026, pending U.S. Drug Enforcement Administration scheduling.

Learn more

Our Stories

View all stories

Recent News

View all news

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

October 23, 2026

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

October 19, 2026

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

October 15, 2026

Takeda to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29

October 15, 2026

Learn more about Takeda

Join Us

Work with globally diverse colleagues who are committed to challenging one another to achieve more together.

Learn more

Investors

Discover how we're unlocking growth potential through bold innovation and a robust pipeline.

Learn more

R&D

We’re translating cutting-edge science into therapies that address urgent patient needs and create new standards of care.

Learn more

Sign up for our investors newsletter

As we move forward in a new era for Takeda, stay up to date through our newsletter, featuring our business strategy, progress in research and development, and how we are leveraging AI and other digital technologies to drive innovation.
You can also receive email updates on our press releases, investor events, and more.

Sign up

Takeda Pharmaceuticals: Global Homepage

TakedaEdgeTakeda leads with a generational promise

Unlocking a new era of impact with first-in-class treatments.

Our Stories

Matt’s story: Finding community and purpose with psoriasis

Michelle’s story: Discovering strength through her psoriasis journey

Shatoya’s psoriasis journey: More than a diagnosis

Recent News

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study

First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda to Hold Earnings Call for Fiscal Year 2026 2nd Quarter on October 29

Join Us

Investors

R&D

Sign up for our investors newsletter

Takeda leads with a generational promise